Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine inKRASWild-Type Pancreatic Cancer

11 Jan 2021

Abstract excerpt

PURPOSE It has recently been described that alternative oncogenic drivers may be found in KRAS wild-type ( KRASWT) pancreatic cancers. This study aimed to determine the incidence of targetable gene fusions present in KRASWTpancreatic adenocarcinoma and response to targeted therapy. METHODS One hundred consecutive patients with pancreatic adenocarcinoma who underwent targeted next-generation sequencing using DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Pancreatic and Hepatic Oncology Research
Share to Renal cell carcinoma treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34250383
DOI: 10.1200/po.20.00265

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine inKRASWild-Type Pancreatic CancerPMID 34250383Read ↗

NRG1 Fusions in KRAS Wild-Type Pancreatic CancerSemantic proximity Read ↗

Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer.Semantic proximity Read ↗

Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature.Semantic proximity Read ↗

Precision medicine for KRAS wild-type pancreatic adenocarcinomas.Semantic proximity Read ↗

Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease.Semantic proximity Read ↗

Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.Semantic proximity Read ↗

NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Fusion genes in pancreatic tumorsSemantic proximity Read ↗

Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild‐Type Pancreatic CancerSemantic proximity Read ↗

Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma.Semantic proximity Read ↗

Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel OpportunitiesSemantic proximity Read ↗

Redefining pancreatic cancer management with tumor-agnostic precision medicine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.